諾發集團(01360.HK)擬折價18.89%配股 最多籌2710萬港元
格隆匯12月30日丨諾發集團(01360.HK)公佈,於2022年12月30日,公司與配售代理訂立配售協議,據此,公司擬向不少於六名承配人配售最多3.71億股配售股份,佔經擴大後公司股份約16.67%。每股配售價0.073港元,較12月30日收市價折讓約18.89%。
假設全部配售股份獲悉數配售,配售的估計所得款項總額及所得款項淨額將分別為約2710萬港元及約2520萬港元。公司擬將配售的所得款項淨額用於(i)償還集團的債務;(ii)於機會出現時進行潛在投資;及(iii)補充集團營運資金以支持業務營運。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.